Featured

Autocrine RA production feeds back on DC function

As professional antigen-presenting cells, dendritic cells have been utilized as whole-cell vaccines, but their clinical efficacy has thus far been limited. Fang et al. found that a common protocol of using GM-CSF and IL-4 to induce bone marrow cells...

CD8 co-receptor modulates the specificity profile of the 1G4 TCR against NY-ESO-1

Jones et al. investigated off-target binding of the 1G4 TCR in CD8+ T cells using an MHC-I ligandome screening approach. The native TCR exhibited less off-target binding than the high-affinity therape...

Extracellular vesicles are key mediators for direct antigen transport to draining lymph nodes

Wang and Cheng et al. showed that electrotransfection activated the HSP90–p53–TSAP6 signaling pathway to enhance extracellular vesicle (EV) biogenesis, facilitating antigen transport from muscles to d...

Generation of T cells with reduced off-target cross-reactivities by engineering co-signalling receptors

To improve TCR-T cell specificity without altering the TCR, Cabezas-Caballero et al. explored the impact of TCR co-receptors on ligand discrimination. CD8 KO in NY-ESO-1 or MAGE-A3 TCR-T cells maintai...

Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity

Li, Liu, Guo, and Zhang et al. employed a dual CRISPR-inhibitor and -activator functional Perturb-seq single-cell screening, coupled with in silico genomic analysis of patient-derived tumor and tumor-...

See all for this week

Previous Digests

DC cross-presentation of dead cell F-actin antigens sculpts tumor evolution

January 14, 2026

Type 1 conventional dendritic cells (cDC1s) cross-present tumor antigens to prime CD8+ T cells. DNGR-1 on cDC1s binds to F-actin of dead cells to allow for detection and internalization of necrotic debris, and signaling results in MHC-I processing and...

Friend or foe? EPOR helps cDC1s make the call

January 7, 2026

The priming of an immune response is a complex process that is largely dependent on the functional state of cDC1s, which can induce either immunogenic or tolerogenic priming, depending on a number of conditions. While numerous factors associated with...

Bringing in neutrophils to improve CAR-T efficacy in solid tumors

December 17, 2025

Several challenges limit CAR T cell efficacy in solid tumors, including the immunosuppressive tumor microenvironment (TME), tumor heterogeneity, and downregulation of CAR target antigen expression on tumor cells. In a recent publication in Cancer Cell, Zuo et al. assessed...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials